For Canadians seeking a non-mRNA COVID vaccine, lack of Novavax shot is 'unfair'
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.
Should the federal government provide a non-mRNA vaccine for COVID-19 this respiratory virus season?
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.
Health Canada approves updated Novavax COVID-19 vaccine
Health Canada authorized Novavax’s updated COVID-19 vaccine that protects against currently circulating variants of the virus on Thursday. The protein-based vaccine, called Nuvaxovid, targets the JN.1 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 Omicron subvariant, the agency said in an online update.
Canadian government not ordering Novavax's protein-based COVID-19 vaccine this year
The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing low demand.
Make Room, mRNA: What to Know About the Novavax COVID Vaccine
In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season.
Canada not ordering Novavax protein-based COVID vaccine this year due to low demand
The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing lack of demand. It says the manufacturer requires a minimum order of its updated protein-based vaccine,
Updated COVID, flu vaccines arrive in London region, and health officials suggest you get both
High risk populations are eligible for the shots for now, and the general population will have to wait until the end of the ...
Fall 2024 COVID-19 guide: The status of COVID in Canada, available vaccines — and strains expected to dominate winter
Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...
Novavax in 2024: What to expect?
Novavax (NASDAQ:NVAX), the biotech behind the Nuvaxovid COVID-19 shot, was no exception. Following an over 26-fold rise in ...